Ocular Therapeutix Inc (OCUL)

[Whalatane]

Suggest you watch for the KOD data this Sat

In the Phase 1b APEX study results being finalized this Saturday, Kodiak Sciences (KOD) is expected to emphasize that KSI-101 was "well tolerated" with a favorable early safety profile across all doses.
Key Safety Findings (APEX Phase 1b)
While full Week 24 safety tables will be presented this weekend, previous data from the study has already established several benchmarks:
No Serious Drug-Related Adverse Events: Earlier reports from the APEX study indicated that most participants at the top dose levels (5 mg and 10 mg) experienced no major safety issues, with no reports of serious side effects leading to treatment discontinuation.
Steroid-Free Advantage: A major highlight for KOD is that KSI-101 achieved its "drying effect" without typical steroid-related side effects, such as elevated intraocular pressure (glaucoma) or cataract formation.
Clean Inflammatory Profile: Despite targeting inflammatory pathways (IL-6), the drug itself did not trigger significant Intraocular Inflammation (IOI) in the initial cohorts, which was a concern for earlier generations of Kodiak’s platform.
Why Investors Watch Safety This Saturday
The primary reason this data matters is that Kodiak has already advanced the 5 mg and 10 mg doses into two massive Phase 3 studies (PEAK and PINNACLE).
10 mg Safety Confirmation: The 10 mg dose is exceptionally high for a liquid eye injection. If the Saturday data confirms that even the 10 mg group had zero cases of vasculitis or severe inflammation at 24 weeks, it would significantly de-risk the ongoing Phase 3 programs.
Comparison to Competitors: Maintaining a "safe profile" while achieving 90%+ retinal dryness would position KSI-101 as a potentially superior first-line treatment compared to steroid implants that often carry high ocular pressure risks.

KOD uses a thin needle MD's are comfortable with
OCUL uses a larger needle

Kiwi